I

Insecticides (India) Ltd
NSE:INSECTICID

Watchlist Manager
Insecticides (India) Ltd
NSE:INSECTICID
Watchlist
Price: 618.35 INR -0.87% Market Closed
Market Cap: ₹18B

Insecticides (India) Ltd
Investor Relations

Insecticides (India) Ltd. is engaged in the manufacture and distribution of agro-chemicals comprising of technical and formulation. The company is headquartered in Delhi, Delhi. The company went IPO on 2007-05-26. The firm is engaged in the manufacturing activities of agro chemicals, pesticides and technical products for agriculture purposes. The firm operates through Agro Chemicals segment. Its product categories include insecticides, herbicides, fungicides, biologicals and plant growth regulators (PGR). Its insecticides products include Lethal Gold, Mahir, Rockstar, Arrow, Bravo 5000, Indan 4G, Indan SP, Lethal Super 505, Logo, Monocil, Aikido, Phentom, Sargent, Sharp and Super Star. Its herbicides products include Super Racer, Master Stroke, Hakama Super, Hijack, Racer, Selector and Omega. Its fungicides products include Avone Plus, Care, Force 11, Pulsor, Focus, Navi and Himil. Its PGR products include Milstim Max, Kayakalp Pro, Surya Zinc, Myco Raja and Agro Spred Max. The firm's products are available in over 100 formulations and approximately 22 technicals. The company caters to both domestic and international markets.

Show more
Loading
INSECTICID
BSE Sensex 30
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2026
Call Date
Jan 30, 2026
AI Summary
Q3 2026

Revenue Growth: Insecticides (India) Limited delivered 8% revenue growth in Q3 FY '26 despite challenging market conditions and muted farmer activity.

Volume-Led Performance: Growth during the quarter was primarily driven by higher volumes in the B2B segment, while B2C demand remained subdued.

Margin Pressure: Gross margins declined due to a greater B2B share and sustained pricing pressure; maintaining 35% gross margin in H2 is expected to be difficult.

New Products: Five new products were launched in the first 9 months, with strong traction from launches like SPARCLE; another five are planned for the coming kharif season.

Sales Returns: Sales returns reached INR 50 crores for the quarter and INR 200 crores for the year, the highest in IIL's history, mainly due to weak market conditions.

Cautious Guidance: Management expects Q4 to be similar to Q3 with continued margin pressure, but is optimistic for a profitability and margin recovery in FY '27.

Capital Discipline: Focus remains on tight working capital, limited broad-based discounts, and aligning capacity expansion (Dahej, Sotanala) to support long-term growth.

Premiumization Focus: Premium products now make up about 60% of B2C sales; strategy is to further increase this share and gradually reduce the tail of lower-margin generics.

Key Financials
Revenue
INR 1,714 crores
Gross Profit
INR 546 crores
EBITDA
INR 201 crores
PAT
INR 128 crores
B2C Revenue Share
76%
B2B Revenue Share
20%
Exports Revenue Share
4%
B2B Volume Growth
15%
B2C Volume Growth
3% to 4%
Sales Returns (Q3 FY '26)
INR 50 crores
Sales Returns (YTD FY '26)
INR 200 crores
Premium Products Share (B2C)
59% (first 9 months FY '26)
Kaeros Sales (9 months FY '26)
INR 89 crores
Other Earnings Calls

Management

Mr. Hari Chand Aggarwal
Chairman
No Bio Available
Mr. Rajesh Kumar Aggarwal B.Com.
CEO, MD & Executive Director
No Bio Available
Mr. Sandeep Kumar Aggarwal
Chief Financial officer
No Bio Available
Mr. Sandeep Kumar
Chief Compliance Officer & Company Secretary
No Bio Available
Mr. Anil Kumar Goyal
Whole-Time Director
No Bio Available
Mr. Sanjeev Aggarwal
Vice President of Operations
No Bio Available
Mr. S. A. Khan
Senior Manager of Human Resources
No Bio Available
Mr. Srikant S. Satwe
Senior Vice President of International Business
No Bio Available

Contacts

Address
DELHI
DELHI
401-402 Lusa Tower, Azadpur Commercial Complex ,
Contacts